F10 and Cirrhosis: Regarding direct oral anticoagulants (DOACs), in a recent comprehensive review, all direct FXa inhibitors appear to have an acceptable safety profile for patients with CTP A cirrhosis, while apixaban and edoxaban seem to be more appropriate for patients with CTP B cirrhosis.